Benzene Ring Bonded Directly To The Diazole Ring By Nonionic Bonding Patents (Class 514/391)
-
Patent number: 7601748Abstract: This invention relates to anti-androgenic N-[?-[3-[4-cyano-3-(trifluoromethyl)-phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]alkyl]-substituted pyrrolidines of general formula I, with a strongly pronounced antiproliferative profile of action; process for the production of the compounds of general formula I, pharmaceutical preparations and the use for the production of pharmaceutical agents.Type: GrantFiled: August 9, 2006Date of Patent: October 13, 2009Assignee: Bayer Schering Pharma AGInventors: Arwed Cleve, Volker Schulze, Dieter Zopf, Jens Hoffmann, Andreas Reichel, Karsten Parczyk
-
Publication number: 20090247587Abstract: The object is to provide a novel LXR? agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. The solving means is a 1,3-dihydroisobenzofuran derivative represented by the following general formula (1) or salt thereof, or their solvate.Type: ApplicationFiled: March 30, 2009Publication date: October 1, 2009Applicant: KOWA COMPANY, LTD.Inventors: Ayumu OKUDA, Takayuki MATSUDA, Toru MIURA, Koichi YAMAZAKI, Yuki YAMAGUCHI, Minoru KOURA, Sayaka KUROBUCHI, Yuuichiro WATANABE, Kimiyuki SHIBUYA
-
Publication number: 20090221539Abstract: A method for preventing or reducing boar taint, a method of screening pigs to determine those more likely to have reduced boar taint and a method for screening substances that enhance skatole metabolism or androstenone in a pig, are disclosed These methods involve the use of the nuclear receptors constitutive androstane receptor, pregnane X receptor and farnesoid X receptor, which have been found to modulate the activity of the enzymes involved in skatole and/or androsterone metabolismType: ApplicationFiled: December 13, 2006Publication date: September 3, 2009Applicant: UNIVERSITY OF GUELPHInventors: E. James Squires, John Peacock, James Gilmore, Philip Sinclair, Michael Terner
-
Publication number: 20090209605Abstract: The present invention concerns nematicidal compounds, their formulation as nematicidal composition and their use for controlling nematodes, preferably plant parasitic nematodes.Type: ApplicationFiled: April 29, 2009Publication date: August 20, 2009Applicant: Devgen N.V.Inventors: Jan Octaaf De Kerpel, Dirk Leysen
-
Publication number: 20090170920Abstract: The present invention relates to compounds of the formula methods for the preparation thereof, and methods for their use. The compounds are useful in treating diseases characterized by the hyperactivity of MEK. Accordingly the compounds are useful in the treatment of diseases, such as cancer, cognitive and CNS disorders, and inflammatory/autoimmune diseases.Type: ApplicationFiled: December 10, 2008Publication date: July 2, 2009Inventors: Shaoqing Chen, Nicholas J.S. Huby, Norman Kong, Jonh Anthony Moliterni, Omar Jose Morales
-
Publication number: 20090137586Abstract: This invention relates to compounds of the Formula (I): or a pharmaceutically acceptable salt, solvate, ester or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.Type: ApplicationFiled: December 18, 2008Publication date: May 28, 2009Inventors: Wensheng Yu, Ling Tong, Lei Chen, Joseph A. Kozlowski, Brian J. Lavey, Neng-Yang Shih, Vincent S. Madison, Guowei Zhou, Peter Orth, Zhuyan Guo, Michael K.C. Wong, De-Yi Yang, Seong Heon Kim, Bandarpalle B. Shankar, M. Arshad Siddiqui, Kristin E. Rosner, Chaoyang Dai, Janeta Popovici-Muller, Vinay M. Girijavallabhan, Dansu Li, Razia Rizvi, Aneta M. Micula, Robert Feltz
-
Publication number: 20090118215Abstract: A novel method for the preparation of a highly densified and at least partly, preferably fully or almost fully hydrated ceramic for use in the preparation of a pharmaceutical composition notably for controlled-release of one or more therapeutically, prophylactically and/or diagnostically active substance. The method involves a concomitant step of hydrating and densifying a bioresorbable and hydratable ceramic such as calcium sulphate. The invention also relates to compositions comprising such a highly densified ceramic. The pharmaceutical composition is useful for targeted and controlled local prolonged release of active substances, e.g. anti-cancer agents, whereby the spectrum and severity of side effects are minimized due to an optimized local concentration-time profile.Type: ApplicationFiled: March 14, 2007Publication date: May 7, 2009Applicant: Lidds ABInventors: Hans Lennernas, Niklas Axen
-
Publication number: 20090111864Abstract: The present invention relates to diarylhydantoin compounds and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.Type: ApplicationFiled: October 24, 2008Publication date: April 30, 2009Applicant: The Regents of the University of CaliforniaInventors: MICHAEL E. JUNG, Dongwon Yoo, Charles L. Sawyers, Chris Tran
-
Patent number: 7524851Abstract: The present invention provides diagnostic methods for predicting therapeutic efficacy in an individual being treated for an autoimmune or an inflammatory disease. In addition, the present invention also provides novel methods for monitoring azathioprine therapy or optimizing clinical responsiveness to azathioprine therapy in an individual by measuring 6-thioguanosine nucleotide levels in a sample from the individual.Type: GrantFiled: December 2, 2004Date of Patent: April 28, 2009Assignee: Robert Bosch Gesellschaft fur Medizinische Forschung (RBMF)Inventors: Markus F. Neurath, Matthias Schwab
-
Publication number: 20090099243Abstract: The invention relates to compound of the formula (I) in which the substituents are as defined in the specification; in free base form or in acid addition salt form; to its preparation, to its use as medicament and to medicaments comprising it.Type: ApplicationFiled: October 15, 2008Publication date: April 16, 2009Inventors: Joachim Nozulak, David Orain
-
Publication number: 20090062361Abstract: Disclosed herein is a compound represented by a formula Therapeutic methods, compositions, and medicaments related thereto are also disclosed.Type: ApplicationFiled: August 15, 2008Publication date: March 5, 2009Applicant: ALLERGAN, INC.Inventor: David W. Old
-
Publication number: 20090030056Abstract: The present invention is directed to novel phenyloin derivative compounds and the use of such compounds as sodium channel blockers. Such compositions have utility as anti-cancer agents and can be used to limit or prevent PCa growth and/or metastasis.Type: ApplicationFiled: September 11, 2008Publication date: January 29, 2009Applicant: University of Virginia Patent FoundationInventor: Milton L. Brown
-
Publication number: 20080306091Abstract: The present invention provides a 2-amino-5-heteroaryl-5-phenylimidazolone compound of formula I The present invention also provides methods for the use thereof to inhibit ?-secretase (BACE) and treat ?-amyloid deposits and neurofibrillary tanglesType: ApplicationFiled: July 28, 2008Publication date: December 11, 2008Applicant: WyethInventors: Michael Sotirios Malamas, Ping Zhou, William Floyd Fobare, William Ronald Solvibile, Iwan Suwandi Gunawan, James Joseph Erdei, Yinfa Yan, Patrick Michael Andrae, Dominick Anthony Quagliato
-
Publication number: 20080286205Abstract: A method for treating prostate related diseases in a subject, the method comprising i) optionally administering to subject an initial boost dose of one or more active substances and/or prodrugs, and ii) administering locally into the prostate a controlled release pharmaceutical composition comprising one or more active substances in a biodegradable ceramic carrier. The biodegradable hydrating ceramic may be selected from the group consisting of non-hydrated or hydrated calcium sulphate, calcium phosphate, calcium carbonate, calcium fluoride, calcium silicate, magnesium sulphate, magnesium phosphate, magnesium carbonate, magnesium fluoride, magnesium silicate, barium sulphate, barium phosphate, barium carbonate, barium fluoride, barium silicate, or mixtures thereof. In a specific embodiment, the biodegradable hydrating ceramic is non-hydrated or hydrated calcium sulphate.Type: ApplicationFiled: March 31, 2006Publication date: November 20, 2008Applicant: Lidds AbInventors: Hans Lennernas, Bo Lennernas, Jonas Hugosson, Niklas Axen
-
Patent number: 7429570Abstract: The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes the step of determining the level of one or more 6-mercaptopurine metabolites in the patient having an immune-mediated gastrointestinal disorder.Type: GrantFiled: March 21, 2007Date of Patent: September 30, 2008Assignee: Hopital Sainte-JustineInventors: Ernest G. Seidman, Yves Theoret
-
Patent number: 7425546Abstract: The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes the step of determining the level of one or more 6-mercaptopurine metabolites in the patient having an immune-mediated gastrointestinal disorder.Type: GrantFiled: March 22, 2007Date of Patent: September 16, 2008Assignee: Hopital Sainte-JustineInventors: Ernest G. Seidman, Yves Theoret
-
Publication number: 20080221086Abstract: The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein R1 represents heteroaryl; -carbocyclyl-heteroaryl; -alkenylheteroaryl or -alkylheteroaryl; R2 represents alkyl which may optionally be substituted by hydroxy; carbocyclyl, which may optionally be substituted by one or more groups selected from alkyl and hydroxy; aryl; -aryl-heteroaryl; -heteroaryl-aryl; -aryl-heterocyclyl; H; heteroaryl; or heterocyclyl, which may optionally be substituted by one or more groups selected from alkyl oxo and hydroxy; R3 represents alkyl which may optionally be substituted by one of more groups selected from alkoxy, amine, hydroxy and —C(O)Oalkyl; carbocyclyl, which may optionally be substituted by one or more groups selected from alkyl haloalkyl, alkoxy, amine, hydroxy and —C(O)Oalkyl; -alkyl-aryl; -alkyl(aryl)2; -alkyl-heteroaryl; -alkyl(heType: ApplicationFiled: November 8, 2007Publication date: September 11, 2008Applicant: PROBIODRUG AGInventors: Michael Thormann, Michael Altmstetter, Andreas Treml, Ulrich Heiser, Mirko Buchholz, Andre J. Niestroj
-
Publication number: 20080176862Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.Type: ApplicationFiled: December 19, 2007Publication date: July 24, 2008Applicants: ASTRAZENECA AB, ASTEX THERAPEUTICS LIMITEDInventors: Stefan Berg, Jorg Holenz, Sofia Karlstrom, Jacob Kihlstrom, Johan Lindstrom, Laszlo Rakos
-
Publication number: 20080153824Abstract: Method for controlling rust infections in leguminous plants by using orysastrobin, mixtures of orysastrobin and a fungicidally active compound II from the group of the azoles, acylalanines, amine derivatives, anilinopyrimidines, dicarboximides, dithiocarbamates, heterocylic compounds, phenylpyrroles, cinnamides, and analogs, or other fungicides according to the description, and also compositions and seed comprising these mixtures.Type: ApplicationFiled: December 16, 2005Publication date: June 26, 2008Applicant: BASF AktiengesellschaftInventors: John-Bryan Speakman, Reinhard Stierl, Siegfried Strathmann, Peter Dombo, Matthias Niedenbruck, Egon Haden, Dirk Voeste, Ulf Groeger
-
Patent number: 7354933Abstract: The present invention relates to a cyclic urea compound of formula I: as defined herein. The invention is also directed to the process for its preparation, pharmaceutical composition comprising it and its pharmaceutical use, as an inhibitor on a protein kinase. Thus, it is useful for preventing or treating a physiological disorder capable of being modulated by inhibiting the activity of a protein kinase, such as a solid tumor.Type: GrantFiled: February 2, 2004Date of Patent: April 8, 2008Assignee: Aventis Pharma SAInventors: Marcel Patek, Anil Nair, Augustin Hittinger, Conception Nemecek, Daniel Bond, Greg Harlow, Herve Bouchard, Jacques Mauger, Jean-Luc Malleron, Mark Palermo, Fahad Al-Obeidi, Thomas Faitg, Hartmut Strobel, Sven Ruf, Kurt Ritter, Youssef El-Ahmad, Dominique Lesuisse, Didier Bénard
-
Publication number: 20080058397Abstract: A compound having a structure is disclosed herein. Therapeutic methods, compositions, and medicaments related thereto are also disclosed.Type: ApplicationFiled: August 30, 2007Publication date: March 6, 2008Inventor: David W. Old
-
Patent number: 7326694Abstract: The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes the step of determining the level of one or more 6-mercaptopurine metabolites in the patient having an immune-mediated gastrointestinal disorder.Type: GrantFiled: May 26, 2006Date of Patent: February 5, 2008Assignee: Hopital Sainte-JustineInventors: Ernest G. Seidman, Yves Theoret
-
Publication number: 20080025972Abstract: Sex steroid potentiated disorders including, prostate cancer and breast cancer, in a patient in need of treatment thereof, are treated with an amount of nitric oxide donating compound and/or nitrosoglutathione reductase inhibitor and/or cysteine binder different from that provided by nitric oxide donating compound effective to inhibit activation of steroid receptor. Variations include using only nitric oxide donating agent as treating agent; using only nitrosoglutathione reductase inhibitors as treating agent, using nitric oxide donating agent plus nitrosoglutathione reductase inhibiting agent; for prostate cancer treatment using prostate cancer drug modified to contain nitric oxide donating moiety or FDA approved nitric oxide donating agent and FDA approved prostate cancer treating agent. Also disclosed is an assay for assessing mutagenic potential of prostate cancer in a patient.Type: ApplicationFiled: May 21, 2007Publication date: January 31, 2008Applicant: Duke UniversityInventors: Yehia Daaka, Jonathan S. Stamler
-
Publication number: 20080020981Abstract: The present invention provides for compounds useful for treating an HIV infection, or preventing an HIV infection, or treating AIDS or ARC. The compounds of the invention are of formula I wherein R1, R2, R3, R4, X1 and X2 are as herein defined. Also disclosed in the present invention are methods of treating an HIV infection with compounds defined herein and pharmaceutical compositions containing said compounds.Type: ApplicationFiled: July 20, 2007Publication date: January 24, 2008Inventor: Zachary Kevin Sweeney
-
Patent number: 7271188Abstract: The present invention provides a compound represented by formula (I): [Formula 1] wherein n is an integer selected from 1 to 20, and R1 and R2, which may be the same or different, each represent a hydrogen atom, or a linear or branched C1-C6 alkyl group, or a salt, a prodrug or a solvate thereof, as well as a drug, a pharmaceutical composition containing the compound, and the like.Type: GrantFiled: June 11, 2004Date of Patent: September 18, 2007Assignee: Chugai Seikayu Kabushiki KaishaInventors: Kazutaka Tachibana, Haruhiko Sato, Masateru Ohta, Mitsuaki Nakamura, Takuya Shiraishi, Ikuhiro Imaoka, Hitoshi Yoshino, Masahiro Nagamuta, Hiromitsu Kawata
-
Patent number: 7144908Abstract: The present invention relates to novel compounds of formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.Type: GrantFiled: March 4, 2002Date of Patent: December 5, 2006Assignee: Glaxo Group LimitedInventors: Diane Mary Coe, Michael John Monteith, Panayiotis Alexandrou Procopiou
-
Patent number: 7138421Abstract: This invention relates to anti-androgenic N-[?-[3-[4-cyano-3-(trifluoromethyl)-phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]alkyl]-substituted pyrrolidines of general formula I, with a strongly pronounced antiproliferative profile of action; process for the production of the compounds of general formula I, pharmaceutical preparations and the use for the production of pharmaceutical agents.Type: GrantFiled: May 10, 2004Date of Patent: November 21, 2006Assignee: Schring AktiengesellschaftInventors: Arwed Cleve, Volker Schulze, Dieter Zopf, Jens Hoffmann, Andreas Reichel, Karsten Parczyk
-
Patent number: 7105497Abstract: The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes the step of determining the level of one or more 6-mercaptopurine metabolites in the patient having an immune-mediated gastrointestinal disorder.Type: GrantFiled: June 14, 2005Date of Patent: September 12, 2006Assignee: Hôpital Sainte-JustineInventors: Ernest G. Seidman, Yves Theoret
-
Patent number: 7081469Abstract: Vascular damaging agents composed of substituted 5(6)-substituted benzimidazole-2-carbamates are provided. These agents are useful in the preparation of medicaments for the treatment of diseases involving neovascularisation, particularly for the treatment of solid tumors, macular degeneration, diabetic retinopathy, rheumatoid arthritis, psoriasis, and atherosclerosis. Embodiments include a 5(6)-substituted benzimidazole-2-carbamate of formula I wherein A represents a multi-substituted alkyl group or aromatic ring.Type: GrantFiled: July 3, 2003Date of Patent: July 25, 2006Assignee: Angiogene Pharmaceuticals Ltd.Inventor: Peter David Davis
-
Patent number: 7019004Abstract: The invention provides compounds of formula (I) wherein X, Y, R1, R2, R3 and R4 are as defined in the description, and the preparation thereof.Type: GrantFiled: May 7, 2001Date of Patent: March 28, 2006Assignee: Novartis AGInventors: Daniel Berney, Robin Breckenridge, Peter Neumann, Gideon Shapiro, Max Peter Seiler, Thomas J. Troxler
-
Patent number: 6987097Abstract: The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes the step of determining the level of one or more 6-mercaptopurine metabolites in the patient having an immune-mediated gastrointestinal disorder.Type: GrantFiled: November 6, 2003Date of Patent: January 17, 2006Assignee: Hospital Sainte-JustineInventors: Ernest G. Seidman, Yves Théorêt
-
Patent number: 6982097Abstract: This invention relates to biocidal compositions and methods of using same. Also provided is a process for the manufacturing of a biocidal composition in the form of a tablet and a method of using the biocidal compositions for the disinfection of water that may contain microorganisms and biofilms.Type: GrantFiled: July 15, 2003Date of Patent: January 3, 2006Assignee: Sani-Care Salon Products, Inc.Inventors: Su Mingzhong, Long Truong Hoang, Linh Truong Hoang
-
Patent number: 6875438Abstract: A preparation comprising at least one form of lipid nanoparticles or a nanoemulsion comprising at least one compound of the formula I and/or one stereoisomeric form of the compound of the formula I and/or one physiologically tolerated salt of the compound of the formula I, in which R1 is —(C5-C17)-alkyl or —(C5-C17)-alkenyl, is suitable for the treatment of androgenic alopecia, of hirsutism, that is to say to prevent unwanted hair growth, and for the treatment of seborrhea and acne and can furthermore be employed in cosmetics.Type: GrantFiled: April 24, 2003Date of Patent: April 5, 2005Assignee: Aventis Pharma Deutschland GmbHInventors: Karl Theodor Kraemer, Karl-Heinz Nietsch, Rainer Pooth, Uwe Muenster, Wolfgang Mehnert, Monika Schaefer-Korting
-
Patent number: 6864273Abstract: The present invention concerns compounds of formula (I) a stereochemically isomeric form thereof, an N-oxide form thereof or a pharmaceutically acceptable acid addition salt thereof, wherein —Z1—Z2— is a bivalent radical; R1, R2 and R3 are each independently selected from hydrogen, C1-6alkyl, hydroxy, halo and the like; or when R1 and R2 are on adjacent carbon atoms, R1 and R2 taken together may form a bivalent radical of formula; Alk1 and Alk2 are optionally substituted C1-6alkanediyl; R6 is hydrogen or phenylmethyl; R5 is a radical of formula wherein n is 1 or 2; p1 is 0, and p2 is 1 or 2; or p1 is 1 or 2, and p2 is 0; X is oxygen, sulfur or ?NR9; Y is oxygen or sulfur; R7 is hydrogen, C1-6alkyl, C3-6cycloalkyl, phenyl or phenylmethyl; R8 is C1-6alkyl, C3-6cycloalkyl phenyl or phenylmethyl; R9 is cyano, C1-6alkyl, C3-6cyclo-alkyl, C1-6alkyloxycarbonyl or aminocarbonyl; R10 is hydrogen or C1-6alkyl; and Q is a bivalent radical.Type: GrantFiled: May 23, 2000Date of Patent: March 8, 2005Assignee: Janssen Pharmaceutica N.V.Inventors: Kristof Van Emelen, Marcel Frans Leopold De Bruyn
-
Patent number: 6812237Abstract: Compounds of the formula (I), wherein R1 is aryl or biaryl; R2 is aryl-lower alkyl, biaryl-lower alkyl, benzo-fused cycloalkyl, cycloalkyl-lower alkyl, bicycloalkyl-lower alkyl, aryloxy-lower alkyl, or aryl-C2-C7-alkyl in which C2-C7-alkyl is interrupted by Y; Y is O, S, SO, SO2, CO or NR6; R3 is hydrogen or lower alkyl; or R2 and R3 combined are C2-C7-alkylene or C2-C7-alkylene interrupted by Y; R4 is hydrogen or lower alkyl; R5 is hydrogen, optionally substituted lower alkyl, aryl-lower alkyl, biaryl-lower alkyl, cycloalkyl-lower alkyl, bicycloalkyl-lower alkyl, aryloxy-lower alkyl, or aryl-C2-C7-alkyl in which C2-C7-alkyl is interrupted by Y; R6 is hydrogen, lower alkyl or aryl-lower alkyl; and pharmaceutically acceptable salts thereof, which are useful as cysteine cathepsin inhibitorsType: GrantFiled: November 7, 2002Date of Patent: November 2, 2004Assignee: Novartis AGInventors: Scott Douglas Cowen, Paul David Greenspan, Leslie Wighton McQuire, Ruben Alberto Tommasi, John Henry Van Duzer
-
Patent number: 6794406Abstract: The invention relates to new indole derivatives, processes for their preparation, and their use in medicaments.Type: GrantFiled: December 21, 2001Date of Patent: September 21, 2004Assignee: Bayer AktiengesellschaftInventors: Helmut Haning, Michael Woltering, Gunter Schmidt, Hilmar Bischoff, Axel Kretschmer, Verena Vöhringer, Christiane Faeste
-
Patent number: 6753339Abstract: The invention concerns fungicide compositions comprising a compound (I) which is (4-S)-4-mehtyl-2-methylthio-4-phenyl-1-phenylamino-2-imidazoline-5-one and a compound (II) which is N1-[(R)-1-(6-fluoro-2-benzothiazolyl)ethyl]-N2-isopropoxycarbonyl-L-validamide or isopropyl[2-methyl-1-(phenylethyl-carbamoyl)propyl]carbamate; the compound (I)/compound (II) ratio ranges between 10 and 0.01, preferably between 5 and 0.5. The invention also concerns a method for eradicating or preventing phytopathogenic fungi in crops, characterized in that it consists in applying on the aerial parts of plants an efficient and non-phytotoxic amount of one of said fungicide compositions.Type: GrantFiled: May 18, 2001Date of Patent: June 22, 2004Assignee: Aventis Cropscience SAInventors: Maurice Chazalet, Patrice Duvert, Jean-Marie Gouot, Richard Mercer
-
Patent number: 6680302Abstract: The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes the step of determining the level of one or more 6-mercaptopurine metabolites in the patient having an immune-mediated gastrointestinal disorder.Type: GrantFiled: December 27, 2001Date of Patent: January 20, 2004Assignee: Hospital Sainte-JustineInventors: Ernest G. Seidman, Yves Théorêt
-
Patent number: 6667334Abstract: The present invention relates to imidazolidine derivatives of the formula I, in which B, E, W, Y, R, R2, R3, R30, e and h have the meanings indicated in the claims. The compounds of the formula I are valuable pharmaceutical active compounds, which are suitable, for example, for the therapy and prophylaxis of inflammatory disorders, for example of rheumatoid arthritis, or of allergic disorders. The compounds of the formula I are inhibitors of the adhesion and migration of leukocytes and/or antagonists of the adhesion receptor VLA-4 belonging to the integrins group. They are generally suitable for the therapy or prophylaxis of diseases which are caused by an undesired extent of leukocyte adhesion and/or leukocyte migration or are associated therewith, or in which cell-cell or cell-matrix interactions which are based on interactions of VLA-4 receptors with their ligands play a part.Type: GrantFiled: March 12, 2001Date of Patent: December 23, 2003Assignee: Aventis Pharma Deutschland GmbHInventors: Bernhard Neises, Volkmar Wehner, Hans Ulrich Stilz
-
Patent number: 6548487Abstract: A method for promoting vesical mucosa epithelium dilatation and/or healing vesical mucosa of a patient's bladder, comprising: administering to the inside of the patient's bladder a solution comprising hyaluronic acid and/or a pharmaceutically acceptable salt thereof in an amount of more than 0.3 to less than 0.6% by weight until promotion of vesical mucosa epithelium dilatation and/or healing vesical mucosa is observed, and a kit comprising a solution containing more than 0.3% by weight and less than 0.6% by weight of hyaluronic acid and/or a pharmaceutically acceptable salt thereof, and a container which contains the solution and is adapted for administration of the solution to the inside of a bladder.Type: GrantFiled: February 7, 2001Date of Patent: April 15, 2003Assignee: Seikagaku CorporationInventors: Katsuya Takahashi, Satoshi Miyauchi
-
Patent number: 6531499Abstract: Peptoid compounds of Formula I and Formula II are disclosed The compounds are useful in the treatment of matrix metalloproteinase-mediated disorders.Type: GrantFiled: July 23, 2001Date of Patent: March 11, 2003Assignee: Wisconsin Alumni Research FoundationInventors: Donald T. Witiak, Paul J. Bertics, Yingsheng Zhang
-
Patent number: 6525086Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, A, X, T, Q, Z, U, Y, Ar, p and n are as defined in the specification. These compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).Type: GrantFiled: March 14, 2001Date of Patent: February 25, 2003Assignee: Novo Nordisk A/SInventors: Lone Jeppesen, Paul Stanley Bury, Per Sauerberg
-
Patent number: 6521654Abstract: Substituted imidazolidine derivatives of the formula I, in which B, E, W, Y, R, R2, R3, R30, e and h have the meanings indicated in the claims. The compounds of the formula I are valuable pharmaceutical active compounds, which are suitable, for example, for the therapy and prophylaxis of inflammatory disorders, for example of rheumatoid arthritis, or of allergic disorders. The compounds of the formula I are inhibitors of the adhesion and migration of leucocytes and/or antagonists of the adhesion receptor VLA-4 belonging to the integrins group. They are generally suitable for the therapy or prophylaxis of illnesses which are caused by an undesired extent of leucocyte adhesion and/or leucocyte migration or are associated therewith, or in which cell-cell or cell-matrix interactions which are based on interactions of VLA-4 receptors with their ligands play a part.Type: GrantFiled: September 14, 2001Date of Patent: February 18, 2003Assignee: Aventis Pharma Deutschland GmbHInventors: Volkmar Wehner, Hans Ulrich Stilz, Wolfgang Schmidt, Dirk Seiffge
-
Patent number: 6469059Abstract: A fungicidal composition for paddy-rice plants has as active ingredients N-(1-cyano-1,2-dimethylpropyl)-2-(2,4-dichlorophenoxy)propanamide in combination with one or more compounds selected from fungicidally active compounds. The combination is useful in a method for disease control of paddy-rice plants.Type: GrantFiled: June 24, 1999Date of Patent: October 22, 2002Assignee: BASF AktiengesellschaftInventors: Tsutomu Nishiguchi, Sohkichi Tajima, Yoshinobu Yamamoto
-
Patent number: 6462063Abstract: The present invention relates to a novel class of N,N′-di substituted hydantoin hydroxamates capable of inhibiting C-proteinase, and to their use to regulate, modulate and/or inhibit abnormal collagen formation as a therapeutic approach towards the treatment of fibrotic disorders.Type: GrantFiled: February 4, 2000Date of Patent: October 8, 2002Assignee: Fibrogen, Inc.Inventors: Wen-Bin Ho, Udo Bauer
-
Patent number: 6451824Abstract: Compounds of formula (I) are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in the course of which an increased activity of matrix-degrading metalloproteinases is involved.Type: GrantFiled: May 8, 1998Date of Patent: September 17, 2002Assignee: Aventis Pharma Deutschland GmbHInventors: Werner Thorwart, Wilfried Schwab, Manfred Schudok, Burkhard Haase
-
Patent number: 6420410Abstract: A method for inhibiting neoplastic cells and related conditions by exposing them to N,N′-substituted benzimidazol-2-ones.Type: GrantFiled: August 16, 2000Date of Patent: July 16, 2002Assignee: Cell Pathways, Inc.Inventors: Gerhard Sperl, Ulrich Ixkes, Rifat Pamukcu, Gary A. Piazza
-
Patent number: 6403805Abstract: The present invention describes compounds useful for treating warm-blooded animals suffering from disease states related to an abnormal enzymatic or catalytic activity of phosphodiesterase IV (PDE IV), and/or disease states related to a physiologically detrimental excess of cytokines, in particular allergic, atopic and inflammatory diseases, said compounds having the formula the N-oxide forms, the pharmaceutically acceptable acid or base addition salts and the stereochemically isomeric forms thereof.Type: GrantFiled: July 27, 1999Date of Patent: June 11, 2002Assignee: Janssen Pharmaceutica N.V.Inventors: Eddy Jean Edgard Freyne, Gaston Stanislas Marcella Diels, José Ignacio Andrés-Gil, Francisco Javier Fernández-Gadea
-
Publication number: 20020068830Abstract: The present invention describes the use of compounds for the manufacture of a medicament for treating warm-blooded animals suffering from disease states related to an abnormal enzymatic or catalytic activity of phosphodiesterase IV (PDE IV), and/or disease states related to a physiologically detrimental excess of cytokines, in particular allergic, atopic and inflammatory diseases, said compounds having the formula 1Type: ApplicationFiled: July 27, 1999Publication date: June 6, 2002Inventors: EDDY JEAN EDGARD FREYNE, GASTON STANISLAS MARCELLA DIELS, JOSE IGNACIO ANDRES-GIL, FRANCISCO JAVIER FERNANDEZ-GADEA
-
Patent number: RE38934Abstract: A method of N-alkoxyalkylating ureides according to the invention comprises reacting a ureide of structure I with an alkylating agent of structure III in the presence of a basic catalyst in an aprotic reaction medium. The ureide may be a 5,5-disubstituted barbituric acid, or it may be phenytoin, glutethimide, and ethosuximide. The alkylating agent is an ester of a sulfonic acid. The base may be a hydride or amine. A preferred process comprises N-alkoxyalkylating 5,5-diphenyl-barbituric acid with methoxymethyl methanesulfonate in the presence of di-isopropyl ethyl amine and isolating the resultant N,N?-bismethoxymethyl-5,5-diphenyl-barbituric acid. The invention also contemplates the novel compounds N-methoxymethyl-5,5-diphenylbarbituric acid, N-methoxymethyl ethosuximide, and N-methoxymethyl glutethimide, and a method comprising administering them to a patient.Type: GrantFiled: February 27, 2003Date of Patent: January 10, 2006Assignee: Taro Pharmaceutical Industries Ltd.Inventors: Daniela Gutman, Hershel Herzog